TY - JOUR
T1 - Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
AU - Grau, Juan J.
AU - Mesía, Ricard
AU - De La Iglesia-Vicente, Maria
AU - Williams, Estrelania S.
AU - Taberna, Miren
AU - Caballero, Miguel
AU - Larque, Ana Belen
AU - De La Oliva, Jorge
AU - Cordón-Cardo, Carlos
AU - Domingo-Domenech, Josep
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel. All rights reserved.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background: Patients with head and neck squamous cell carcinoma (HNSCC) present different responses to chemotherapy and radiotherapy. One explanation may be the differences in the individual rates of stem cell-like cells. Methods: We included patients with HNSCC and tumor progression or relapse. Tumor samples were obtained before and after primary chemotherapy, and immunohistochemical analyses were performed for CD44, HLA class I (HLA-I), pancytokeratin, and phosphorylated epidermal growth factor receptor (p-EGFR). Differences in expression between the first and second specimens were assessed. Results: Expression between the first and second specimens varied as follows: CD44 increased by 14.67% (95% confidence interval, CI: 6.94 to 22.40; p < 0.01); HLA-I decreased by 16.72% (95% CI: -23.87 to -9.47; p < 0.01); pancytokeratin decreased by 24.91% (95% CI: -32.8 to -17.7; p < 0.01), and p-EFGR expression decreased by 12.30% (95% CI: -20.61 to -3.98; p < 0.005). Conclusions: Among patients with HNSCC, there is an enrichment of cells with stem-like markers in relapsed tumors when compared with the primary tumor. This finding should be considered when developing treatment strategies.
AB - Background: Patients with head and neck squamous cell carcinoma (HNSCC) present different responses to chemotherapy and radiotherapy. One explanation may be the differences in the individual rates of stem cell-like cells. Methods: We included patients with HNSCC and tumor progression or relapse. Tumor samples were obtained before and after primary chemotherapy, and immunohistochemical analyses were performed for CD44, HLA class I (HLA-I), pancytokeratin, and phosphorylated epidermal growth factor receptor (p-EGFR). Differences in expression between the first and second specimens were assessed. Results: Expression between the first and second specimens varied as follows: CD44 increased by 14.67% (95% confidence interval, CI: 6.94 to 22.40; p < 0.01); HLA-I decreased by 16.72% (95% CI: -23.87 to -9.47; p < 0.01); pancytokeratin decreased by 24.91% (95% CI: -32.8 to -17.7; p < 0.01), and p-EFGR expression decreased by 12.30% (95% CI: -20.61 to -3.98; p < 0.005). Conclusions: Among patients with HNSCC, there is an enrichment of cells with stem-like markers in relapsed tumors when compared with the primary tumor. This finding should be considered when developing treatment strategies.
KW - Chemoresistance
KW - Head and neck cancer
KW - Stem-like cells
UR - http://www.scopus.com/inward/record.url?scp=84963579558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963579558&partnerID=8YFLogxK
U2 - 10.1159/000445118
DO - 10.1159/000445118
M3 - Article
C2 - 27077749
AN - SCOPUS:84963579558
SN - 0030-2414
VL - 90
SP - 267
EP - 272
JO - Oncology
JF - Oncology
IS - 5
ER -